nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

08.12.2015 | Original Article

Reproducibility of O-(2-¹⁸F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas

verfasst von: Carina Stegmayr, Michael Schöneck, Dennis Oliveira, Antje Willuweit, Christian Filss, Norbert Galldiks, N. Jon Shah, Heinz H. Coenen, Karl-Josef Langen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Positron emission tomography (PET) using O-(2-¹⁸F-fluoroethyl)-L-tyrosine (¹⁸F-FET) is a well-established method for the diagnostics of brain tumors. This study investigates reproducibility of ¹⁸F-FET uptake kinetics in rat gliomas and the influence of the frequently used dexamethasone (Dex) therapy.

Methods

F98 glioma or 9L gliosarcoma cells were implanted into the striatum of 31 Fischer rats. After 10–11 days of tumor growth, the animals underwent dynamic PET after injection of ¹⁸F-FET (baseline). Thereafter, animals were divided into a control group and a group receiving Dex injections, and all animals were reinvestigated 2 days later. Tumor-to-brain ratios (TBR) of ¹⁸F-FET uptake (18–61 min p.i.) and the slope of the time-activity-curves (TAC) (18–61 min p.i.) were evaluated using a Volume-of-Interest (VOI) analysis. Data were analyzed by two-way repeated measures ANOVA and reproducibility by the intraclass correlation coefficient (ICC).

Results

The slope of the tumor TACs showed high reproducibility with an ICC of 0.93. A systematic increase of the TBR in the repeated scans was noted (3.7 ± 2.8 %; p < 0.01), and appeared to be related to tumor growth as indicated by a significant correlation of TBR and tumor volume (r = 0.77; p < 0.0001). After correction for tumor growth TBR showed high longitudinal stability with an ICC of 0.84. Dex treatment induced a significant decrease of the TBR (−8.2 ± 6.1 %; p < 0.03), but did not influence the slope of the tumor TAC.

Conclusion

TBR of ¹⁸F-FET uptake and tracer kinetics in brain tumors showed high longitudinal stability. Dex therapy may induce a minor decrease of the TBR; this needs further investigation.

Nur mit Berechtigung zugänglich

Galldiks N, Langen KJ. Applications of PET imaging of neurological tumors with radiolabeled amino acids. Q J Nucl Med Mol Imaging: Off Publ Ital Assoc Nucl Med. 2015;59:70–82.

Herholz K, Langen KJ, Schiepers C, Mountz JM. Brain tumors. Semin Nucl Med. 2012;42:356–70.CrossRefPubMedPubMedCentral

Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287–94.CrossRefPubMed

Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med: Off Publ Soc Nucl Med. 1999;40:205–12.

Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte K, et al. Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI. J Nucl Med: Off Publ Soc Nucl Med. 2012;53:1048–57.CrossRef

Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain: J Neurol. 2005;128:678–87.CrossRef

Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, et al. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol. 2009;36:779–87.CrossRefPubMed

Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nussbaumer K, et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging. 2010;37:1521–8.CrossRefPubMed

Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464–70.CrossRefPubMed

10.

Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med: Off Publ Soc Nucl Med. 2007;48:519–27.CrossRef

11.

Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, et al. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med: Off Publ Soc Nucl Med. 2015;56:9–15.CrossRef

12.

Popperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med: Off Publ Soc Nucl Med. 2006;47:393–403.

13.

Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K, et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005;32:422–9.CrossRefPubMed

14.

Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933–42.CrossRefPubMed

15.

Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med. 2011;36:841–7.CrossRefPubMed

16.

Odewole OA, Oyenuga OA, Tade F, Savir-Baruch B, Nieh PT, Master V, et al. Reproducibility and reliability of anti-3-[(1)(8)F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis. Mol Imaging Biol: Off Publ Acad Mol Imaging. 2015;17:277–83.CrossRef

17.

Langen KJ, Roosen N, Coenen HH, Kuikka JT, Kuwert T, Herzog H, et al. Brain and brain tumor uptake of L-3-[123I]iodo-alpha-methyl tyrosine: competition with natural L-amino acids. J Nucl Med: Off Publ Soc Nucl Med. 1991;32:1225–9.

18.

Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;80:176–84.CrossRefPubMed

19.

Kotsarini C, Griffiths PD, Wilkinson ID, Hoggard N. A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: implications for physiological brain imaging of patients with intracranial tumors. Neurosurgery. 2010;67:1799–815.CrossRefPubMed

20.

Sarin R, Murthy V. Medical decompressive therapy for primary and metastatic intracranial tumours. Lancet Neurol. 2003;2:357–65.CrossRefPubMed

21.

Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316–22.CrossRefPubMed

22.

Piroth MD, Prasath J, Willuweit A, Stoffels G, Sellhaus B, van Osterhout A, et al. Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. Nucl Med Biol. 2013;40:795–800.CrossRefPubMed

23.

Langen KJ, Jarosch M, Muhlensiepen H, Hamacher K, Broer S, Jansen P, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol. 2003;30:501–8.CrossRefPubMed

24.

Ewing JR, Brown SL, Nagaraja TN, Bagher-Ebadian H, Paudyal R, Panda S, et al. MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration. J Magn Reson Imaging: JMRI. 2008;27:1430–8.CrossRefPubMedPubMedCentral

25.

Bao Q, Newport D, Chen M, Stout DB, Chatziioannou AF. Performance evaluation of the inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med: Off Publ Soc Nucl Med. 2009;50:401–8.CrossRef

26.

Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot: Incl Data Instrum Methods Use Agric Ind Med. 2002;57:853–6.CrossRef

27.

Miller JN. Basic statistical methods for Analytical Chemistry. Part 2. Calibration and regression methods. A review. Analyst. 1991;116:3–14.CrossRef

28.

Galldiks N, Rapp M, Stoffels G, Dunkl V, Sabel M, Langen KJ. Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2-18F-fluorethyl)-L-tyrosine positron emission tomography in comparison with magnetic resonance imaging. Mol Imaging. 2013;12:273–6.PubMed

29.

Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med: Off Publ Soc Nucl Med. 2011;52:856–64.CrossRef

30.

Popperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspotter M, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005;32:1018–25.CrossRefPubMed

31.

Pöpperl G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, et al. Serial O-(2-[(18)F]fluoroethyl)-L:-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006;33:792–800.CrossRefPubMedPubMedCentral

32.

Nedergaard MK, Michaelsen SR, Urup T, Broholm H, El Ali H, Poulsen HS, et al. 18F-FET MicroPET and MicroMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma. PLoS One. 2015;10:e0115315.CrossRefPubMedPubMedCentral

33.

Nedergaard MK, Kristoffersen K, Michaelsen SR, Madsen J, Poulsen HS, Stockhausen MT, et al. The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts. PLoS One. 2014;9:e100009.CrossRefPubMedPubMedCentral

34.

Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med: Off Publ Soc Nucl Med. 2013;54:2046–54.CrossRef

35.

Jansen NL, Suchorska B, Schwarz SB, Eigenbrod S, Lutz J, Graute V, et al. [18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Mol Imaging. 2013;12:137–47.PubMed

36.

Habermeier A, Graf J, Sandhofer BF, Boissel JP, Roesch F, Closs EI. System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids. 2015;47:335–44.CrossRefPubMed

37.

Lahoutte T, Caveliers V, Franken PR, Bossuyt A, Mertens J, Everaert H. Increased tumor uptake of 3-(123)I-Iodo-L-alpha-methyltyrosine after preloading with amino acids: an in vivo animal imaging study. J Nucl Med: Off Publ Soc Nucl Med. 2002;43:1201–6.

38.

Le Cam A, Freychet P. Effect of glucocorticoids on amino acid transport in isolated rat hepatocytes. Mol Cell Endocrinol. 1977;9:205–14.CrossRefPubMed

39.

Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, et al. [F-18]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncology. 2013;15:341–51.CrossRefPubMedPubMedCentral

40.

Langen KJ, Galldiks N. Reply to “[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma” by Hutterer et al. Neuro-Oncology. 2013;15:816–7.CrossRefPubMedPubMedCentral

41.

Christian N, Lee JA, Bol A, De Bast M, Jordan B, Gregoire V. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol: J Eur Soc Ther Radiol Oncol. 2009;91:101–6.CrossRef

Titel: Reproducibility of O-(2-18F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas
verfasst von: Carina Stegmayr
Michael Schöneck
Dennis Oliveira
Antje Willuweit
Christian Filss
Norbert Galldiks
N. Jon Shah
Heinz H. Coenen
Karl-Josef Langen
Publikationsdatum: 08.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3274-4

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Imaging of differentiated thyroid carcinoma: 124I-PET/MRI may not be superior to 124I-PET/CT

Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer’s disease

[123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies

Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [11C] DASB positron emission tomography study

Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans

Imaging of differentiated thyroid carcinoma: 124I-PET/MRI may not be superior to 124I-PET/CT